Literature DB >> 28297075

Decrease in Statewide Antipsychotic Prescribing after Implementation of Child and Adolescent Psychiatry Consultation Services.

Rebecca P Barclay1, Robert B Penfold2, Donna Sullivan3, Lauren Boydston4, Julia Wignall1, Robert J Hilt1.   

Abstract

OBJECTIVE: To learn if a quality of care Medicaid child psychiatric consultation service implemented in three different steps was linked to changes in statewide child antipsychotic utilization. DATA SOURCES/STUDY
SETTING: Washington State child psychiatry consultation program primary data and Medicaid pharmacy division antipsychotic utilization secondary data from July 1, 2006, through December 31, 2013. STUDY
DESIGN: Observational study in which consult program data were analyzed with a time series analysis of statewide antipsychotic utilization. DATA COLLECTION/EXTRACTION
METHODS: All consultation program database information involving antipsychotics was compared to Medicaid pharmacy division database information involving antipsychotic utilization. PRINCIPAL
FINDINGS: Washington State's total child Medicaid antipsychotic utilization fell from 0.51 to 0.25 percent. The monthly prevalence of use fell by a mean of 0.022 per thousand per month following the initiation of elective consults (p = .004), by 0.065 following the initiation of age/dose triggered mandatory reviews (p < .001), then by another 0.022 following the initiation of two or more concurrent antipsychotic mandatory reviews (p = .001). High-dose antipsychotic use fell by 57.8 percent in children 6- to 12-year old and fell by 52.1 percent in teens.
CONCLUSIONS: Statewide antipsychotic prescribing for Medicaid clients fell significantly at different rates following each implementation step of a multilevel consultation and best-practice education service. © Health Research and Educational Trust.

Entities:  

Keywords:  Antipsychotic agents; Medicaid; child and adolescent psychiatry; outcome assessment (health care); referral and consultation

Mesh:

Substances:

Year:  2017        PMID: 28297075      PMCID: PMC5346490          DOI: 10.1111/1475-6773.12539

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  22 in total

1.  Segmented regression analysis of interrupted time series studies in medication use research.

Authors:  A K Wagner; S B Soumerai; F Zhang; D Ross-Degnan
Journal:  J Clin Pharm Ther       Date:  2002-08       Impact factor: 2.512

2.  Medicaid prior authorization policies for pediatric use of antipsychotic medications.

Authors:  Ian Schmid; Mehmet Burcu; Julie M Zito
Journal:  JAMA       Date:  2015-03-03       Impact factor: 56.272

Review 3.  Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents.

Authors:  Christoph U Correll; Harold E Carlson
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2006-07       Impact factor: 8.829

Review 4.  Use of antipsychotic medications in pediatric populations: what do the data say?

Authors:  Robert B Penfold; Christine Stewart; Enid M Hunkeler; Jeanne M Madden; Janet R Cummings; Ashli A Owen-Smith; Rebecca C Rossom; Christine Y Lu; Frances L Lynch; Beth E Waitzfelder; Karen J Coleman; Karen A Coleman; Brian K Ahmedani; Arne L Beck; John E Zeber; Gregory E Simon
Journal:  Curr Psychiatry Rep       Date:  2013-12       Impact factor: 5.285

5.  The continuing shortage of child and adolescent psychiatrists.

Authors:  Christopher R Thomas; Charles E Holzer
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2006-09       Impact factor: 8.829

6.  Antipsychotic use by medicaid-insured youths: impact of eligibility and psychiatric diagnosis across a decade.

Authors:  Julie Magno Zito; Mehmet Burcu; Aloysius Ibe; Daniel J Safer; Laurence S Magder
Journal:  Psychiatr Serv       Date:  2013-03-01       Impact factor: 3.084

7.  Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.

Authors:  Christoph U Correll; Peter Manu; Vladimir Olshanskiy; Barbara Napolitano; John M Kane; Anil K Malhotra
Journal:  JAMA       Date:  2009-10-28       Impact factor: 56.272

8.  Medication use in US youth with mental disorders.

Authors:  Kathleen R Merikangas; Jian-ping He; Judith Rapoport; Benedetto Vitiello; Mark Olfson
Journal:  JAMA Pediatr       Date:  2013-02       Impact factor: 16.193

9.  The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children.

Authors:  Meredith Matone; Russell Localio; Yuan-Shung Huang; Susan dosReis; Chris Feudtner; David Rubin
Journal:  Health Serv Res       Date:  2012-09-04       Impact factor: 3.402

10.  Atypical antipsychotic use among Medicaid-insured children and adolescents: duration, safety, and monitoring implications.

Authors:  Mehmet Burcu; Julie Magno Zito; Aloysius Ibe; Daniel J Safer
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-04-01       Impact factor: 2.576

View more
  9 in total

Review 1.  High-risk psychotropic medications for US children with trauma sequelae.

Authors:  E R Barnett; M T Concepcion Zayas
Journal:  Epidemiol Psychiatr Sci       Date:  2018-11-05       Impact factor: 6.892

2.  Advancing the Quality of Pediatric Antipsychotic Use: Maybe It Takes a PAL.

Authors:  Julie Magno Zito
Journal:  Health Serv Res       Date:  2017-04       Impact factor: 3.402

3.  Effectiveness of mandatory peer review to reduce antipsychotic prescriptions for Medicaid-insured children.

Authors:  Ayse Akincigil; Thomas I Mackie; Sharon Cook; Robert J Hilt; Stephen Crystal
Journal:  Health Serv Res       Date:  2020-06-21       Impact factor: 3.402

Review 4.  National Child Mental Health Quality Measures: Adherence Rates and Extent of Evidence for Clinical Validity.

Authors:  Bonnie T Zima; Juliet B Edgcomb; Samantha A Shugarman
Journal:  Curr Psychiatry Rep       Date:  2019-01-31       Impact factor: 5.285

5.  Designing Safer Use of Antipsychotics Among Youths: A Human-Centered Approach to an Algorithm-Based Solution.

Authors:  Andrea L Hartzler; James D Ralston; Terry A Hannan; Kelly J Kelleher; Robert B Penfold
Journal:  Psychiatr Serv       Date:  2019-07-16       Impact factor: 3.084

6.  Development of a Symptom-Focused Model to Guide the Prescribing of Antipsychotics in Children and Adolescents: Results of the First Phase of the Safer Use of Antipsychotics in Youth (SUAY) Clinical Trial.

Authors:  Robert B Penfold; Ella E Thompson; Robert J Hilt; Nadine Schwartz; Adelaide S Robb; Christoph U Correll; Douglas Newton; Kelly Rogalski; Marian F Earls; Robert A Kowatch; Arne Beck; Bobbi Jo H Yarborough; Stephen Crystal; Benedetto Vitiello; Kelly J Kelleher; Gregory E Simon
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2021-05-04       Impact factor: 8.829

7.  Safer use of antipsychotics in youth (SUAY) pragmatic trial protocol.

Authors:  Robert B Penfold; Ella E Thompson; Robert J Hilt; Kelly J Kelleher; Nadine Schwartz; Arne Beck; Gregory N Clarke; James D Ralston; Andrea L Hartzler; R Yates Coley; Mary Akosile; Benedetto Vitiello; Gregory E Simon
Journal:  Contemp Clin Trials       Date:  2020-10-20       Impact factor: 2.226

8.  High-level psychotropic polypharmacy: a retrospective comparison of children in foster care to their peers on Medicaid.

Authors:  Deborah Winders Davis; W David Lohr; Yana Feygin; Liza Creel; Kahir Jawad; V Faye Jones; P Gail Williams; Jennifer Le; Marie Trace; Natalie Pasquenza
Journal:  BMC Psychiatry       Date:  2021-06-10       Impact factor: 3.630

9.  Trends Over Time in Antipsychotic Initiation at a Large Children's Health Care System.

Authors:  Laura J Chavez; Kelly J Kelleher; Arne Beck; Gregory N Clarke; Robert B Penfold
Journal:  J Child Adolesc Psychopharmacol       Date:  2021-06       Impact factor: 3.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.